Summary Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-
mediated autoimmune diseases of the neuromuscular junction that usually present with …

Myasthenia gravis (MG) is a neurological autoimmune disorder characterized by muscle
weakness and fatigue. It is a B cell–mediated disease caused by pathogenic antibodies …

Multiple sclerosis (MS) is a chronic and debilitating neurological disease that results in
inflammatory demyelination. While endogenous remyelination helps to recover function, this …

Background In the demyelinating disease multiple sclerosis (MS), chronic-active brain
inflammation, remyelination failure and neurodegeneration remain major issues despite …

Current multiple sclerosis (MS) therapies are effective in reducing relapse rate, short-term
measures of disability, and magnetic resonance imaging (MRI) measures of inflammation in …

Multiple sclerosis (MS), a debilitating autoimmune inflammatory disease that affects the
brain and spinal cord, causes demyelination of neurons, axonal damage, and …

Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling
weakness through a compromise of neuromuscular transmission. The disease fulfills strict …

Regulatory T cells play a key role in immune tolerance to self‐antigens, thereby preventing
autoimmune diseases. However, no drugs targeting Treg cells have been approved for …

Objectives Ocrelizumab (OCR) is a humanized monoclonal antibody targeting CD20 antigen
exposed on B cells surface. Kinetic of B-cells repopulation after depletion therapy shows …

We have previously reported evidence that Nogo-A activation of Nogo-receptor 1 (NgR1)
can drive axonal dystrophy during the neurological progression of experimental …